Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study.

[1]  J. Cazenave,et al.  Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases , 2007, Journal of thrombosis and haemostasis : JTH.

[2]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[3]  D. Angiolillo,et al.  Platelet function assessment to predict outcomes after coronary interventions: hype or hope? , 2006, Journal of the American College of Cardiology.

[4]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[5]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[6]  E. Trabetti,et al.  Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  C. Macaya,et al.  Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. , 2006, Journal of the American College of Cardiology.

[8]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[9]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[10]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[11]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[12]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[13]  E. Trabetti,et al.  Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. , 2005, The American journal of cardiology.

[14]  D. Baruch,et al.  Clinical researchInterventional cardiologyEnhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis: A Case-Control Study , 2005 .

[15]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[16]  C. Macaya,et al.  High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. , 2004, European heart journal.

[17]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[18]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[19]  P. Gurbel,et al.  Durability of platelet inhibition by clopidogrel. , 2003, The American journal of cardiology.

[20]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[21]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[22]  R. Ferrari,et al.  CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study , 2006 .

[23]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.